Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | COVID-19: the growth of telemedicine, oral agents and disruptions in clinical trial operations

Jan Philipp Bewersdorf, MD, Yale School of Medicine, New Haven, CT, discusses the positive and negative impacts of COVID-19 on various issues. Firstly, Dr Bewersdorf explains that many of his patients like the introduction of telemedicine whereby routine check-ups can be done remotely. The trend towards oral treatments can be seen with the approval of oral decitabine, which is bioequivalent to parenteral decitabine. Pharmacodynamic and pharmacokinetic studies of Phase I trials were disrupted and had to be reorganized since the main priority was to keep as many patients as possible out of the hospital. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.